Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have earned an average recommendation of “Buy” from the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $40.3750.

Several equities analysts recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 12th. BTIG Research began coverage on Oruka Therapeutics in a report on Thursday, May 22nd. They issued a “buy” rating for the company. HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a research note on Monday, August 18th. Finally, Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 16th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Fairmount Funds Management LLC boosted its holdings in Oruka Therapeutics by 5.0% in the fourth quarter. Fairmount Funds Management LLC now owns 3,371,922 shares of the company’s stock valued at $65,382,000 after acquiring an additional 160,000 shares during the last quarter. VR Adviser LLC raised its holdings in shares of Oruka Therapeutics by 6.5% in the 4th quarter. VR Adviser LLC now owns 3,285,620 shares of the company’s stock worth $63,708,000 after purchasing an additional 200,000 shares during the period. RTW Investments LP raised its holdings in shares of Oruka Therapeutics by 5.1% in the 4th quarter. RTW Investments LP now owns 1,945,649 shares of the company’s stock worth $37,726,000 after purchasing an additional 95,001 shares during the period. Braidwell LP lifted its stake in shares of Oruka Therapeutics by 37.0% in the 1st quarter. Braidwell LP now owns 1,572,426 shares of the company’s stock valued at $16,133,000 after purchasing an additional 424,750 shares in the last quarter. Finally, Franklin Resources Inc. grew its holdings in shares of Oruka Therapeutics by 40.6% during the 2nd quarter. Franklin Resources Inc. now owns 1,012,968 shares of the company’s stock worth $11,355,000 after purchasing an additional 292,421 shares during the period. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $15.56 on Wednesday. Oruka Therapeutics has a fifty-two week low of $5.49 and a fifty-two week high of $31.13. The company has a market capitalization of $582.72 million, a price-to-earnings ratio of -5.54 and a beta of -0.26. The stock has a fifty day moving average of $14.01 and a two-hundred day moving average of $11.74.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.02. On average, analysts forecast that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.